NASDAQ: RNTX
Rein Therapeutics Inc Stock Ownership - Who owns Rein Therapeutics?

Insider buying vs selling

Have Rein Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Voss Capital LP10% Owner2025-11-14104,183$1.23
$127.62kBuy
Voss Capital LP10% Owner2025-10-28178,392$1.39
$247.96kBuy
Voss Capital LP10% Owner2025-10-2792,642$1.37
$126.92kBuy
Voss Capital LP10% Owner2025-10-274,840$1.37
$6.63kBuy
Voss Capital LP10% Owner2025-10-2430,176$1.39
$41.94kBuy

1 of 1

RNTX insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when RNTX insiders and whales buy or sell their stock.

RNTX Shareholders

What type of owners hold Rein Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Muneer A. Satter59.24%16,609,449$21.09MInsider
Voss Capital LP15.14%4,243,969$5.39MInstitution
Reinhard J. Ambros9.09%2,549,982$3.24MInsider
Voss Capital LP8.71%2,442,649$3.10MInsider
Novartis Bioventures Ltd7.42%2,079,394$2.64MInsider
Of Texastexas Am Investment Managment Co University6.46%1,810,457$2.30MInsider
University Of Texastexas Am Investment Management Co6.23%1,746,549$2.22MInsider
Bios Capital Management LP6.03%1,690,751$2.15MInstitution
Brian M. Gallagher Jr.5.11%1,431,519$1.82MInsider
Vanguard Group Inc4.16%1,165,807$1.48MInstitution

1 of 3

RNTX vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
RNTX22.93%77.07%Net Buying
CRVO3.05%96.95%Net Buying
BTAI1.76%98.24%
VERU6.75%93.25%
CELU2.23%97.77%Net Selling

Rein Therapeutics Stock Ownership FAQ

Who owns Rein Therapeutics?

Rein Therapeutics (NASDAQ: RNTX) is owned by 38.52% institutional shareholders, 129.44% Rein Therapeutics insiders, and 0.00% retail investors. Muneer A. Satter is the largest individual Rein Therapeutics shareholder, owning 16.61M shares representing 59.24% of the company. Muneer A. Satter's Rein Therapeutics shares are currently valued at $21.59M.

If you're new to stock investing, here's how to buy Rein Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.